当前位置:循环首页>正文

[OCC2012]心肌再生治疗心力衰竭

Myocardial regeneration therapy for heart failure

作者:  I.Komuro   日期:2012/6/11 9:57:47

国际循环网版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

Cardiac hypertrophy is developed as an adaptive response to increased workload. Although cardiac function first remains normal, prolonged cardiac hypertrophy causes heart failure.

  Issei Komuro
  Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan
  Cardiac hypertrophy is developed as an adaptive response to increased workload. Although cardiac function first remains normal, prolonged cardiac hypertrophy causes heart failure. We have recently demonstrated that DNA damage of cardiomyocytes induces p53 accumulation and thus inhibition of angiogenesis, resulting in the transition from cardiac hypertrophy to heart failure. This result suggests that angiogenic therapy might be effective for heart failure.
  We have treated over 100 "no-option" patients with critical limb ischemia by implantation of peripheral blood mononuclear cells. Cell therapy using peripheral blood mononuclear cells was very effective for ~70% of patients with limb ischemia, and its efficacy was associated with increases in plasma levels of angiogenic factors. Implantation of the cells induced regeneration of skeletal muscle and activated satellite cells produced various kinds of angiogenic growth factors, thereby promoting neovascularization in ischemic tissues. We have recently found that implantation of peripheral blood mononuclear cells into heart is also effective to improve cardiac ischemia.
  We have identified a novel cardiomyocyte differentiation factor, IGFBP-4.  IGFBP-4 enhanced cardiomyocyte differentiation in vitro, and knockdown of Igfbp4 attenuated cardiomyogenesis both in vitro and in vivo. The cardiogenic effect of IGFBP-4 was independent of its IGF-binding activity but was mediated by the inhibitory effect on canonical Wnt signalling. We previously found that leukemia inhibitory factor (LIF) protected heart from myocardial infarction at lease by prevention of cardiomyocyte death and angiogenesis.  Recently, we have established a novel system to dissect cardiac regeneration and found that LIF also induces formation of new cardiomyocytes.
  Minamino T, Komuro I et al.  Peripheral-blood or bone-marrow mononuclear cells for therapeutic angiogenesis?  Lancet 360:2083-2084, 2002.
  Zou Y, Komuro I et al.  Leukemia Inhibitory Factor Enhances Survival of Cardiomyocytes and Induces Regeneration of Myocardium After Myocardial Infarction.  Circulation 108:748-753, 2003.
  Sano M, Komuro I et al.  p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload.  Nature 446:444-448, 2007
  Zhu W, Komuro I. et al. IGFBP-4 is an inhibitor of canonical Wnt signalling required for cardiogenesis.  Nature. 454:345-349, 2008

版面编辑:赵书芳  责任编辑:聂会珍



心力衰竭心肌再生治疗

分享到: 更多


设为首页 | 加入收藏 | 关于我们 | 联系方式 | 招贤纳士
声明:国际循环网( www.icirculation.com)对刊载的所有文章、视频、幻灯、音频等资源拥有全部版权。未经本站许可,不得转载。
京ICP备15014970号-5  互联网药品信息服务资格证书编号(京)-非经营性-2017-0063  京公网安备 11010502033353号  增值电信业务经营许可证:京ICP证150541号
国际循环 版权所有   © 2004-2024 www.icirculation.com All Rights Reserved
公司名称:北京美赞广告有限公司 公司地址:北京市朝阳区朝阳门北大街乙12号天辰大厦1座1409 电话:010-51295530